Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.34 |
| ▸ | WNT3A | P56704 | 2/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | EEF2K | O00418 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PTPRC | P08575 | 1/20 | 0.33 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6741372 | 1.00 | MMP2 (0.38) | MMP2MMP13CYP2A6CTNNB1WNT3A | |
| SCHEMBL6738949 | 0.85 | MEP1B (0.41) | MMP2MMP13CYP2A6CTNNB1WNT3A | |
| SCHEMBL6738953 | 0.85 | MEP1B (0.41) | MMP2MMP13CYP2A6CTNNB1WNT3A | |
| SCHEMBL6741376 | 0.84 | MMP2 (0.39) | MMP2MMP13CYP2A6HDAC4HDAC1 | |
| SCHEMBL7061656 | 0.84 | MMP2 (0.39) | MMP2MMP13CYP2A6HDAC4HDAC1 | |
| SCHEMBL6733651 | 0.83 | HDAC4 (0.42) | MMP2MMP13CYP2A6HDAC4OPRM1 | |
| SCHEMBL6733654 | 0.83 | HDAC4 (0.42) | MMP2MMP13CYP2A6HDAC4OPRM1 | |
| SCHEMBL7466758 | 0.82 | MMP2 (0.36) | MMP2MMP13CYP2A6HDAC1 | |
| SCHEMBL7466761 | 0.82 | MMP2 (0.36) | MMP2MMP13CYP2A6HDAC1 | |
| SCHEMBL6739244 | 0.81 | MMP2 (0.39) | MMP2MMP13CYP2A6CTNNB1WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040225006-A1 | (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates | SMITHKLINE BEECHAM P.L.C. | 2004-11-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040225006-A1 | (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates | CD40, TNFRSF1A, CD2 | MMP2 849/4885MMP13 71/4885CYP2A6 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.